scholarly journals MicroRNA-186-5p Inhibits Proliferation And Metastasis Of Esophageal Cancer By Mediating HOXA9

2019 ◽  
Vol Volume 12 ◽  
pp. 8905-8914 ◽  
Author(s):  
Changqin Xu ◽  
Bin Li ◽  
Shulei Zhao ◽  
Bingjie Jin ◽  
Ruzhen Jia ◽  
...  
2021 ◽  
Vol 17 (1) ◽  
pp. 259-270
Author(s):  
Jia-cheng Xu ◽  
Tian-yin Chen ◽  
Le-tai Liao ◽  
Tao Chen ◽  
Quan-lin Li ◽  
...  

2020 ◽  
Vol 158 (6) ◽  
pp. S-1508-S-1509
Author(s):  
Jia-Cheng Xu ◽  
Tao Chen ◽  
Yi-Qun Zhang ◽  
Ping-Hong Zhou

2020 ◽  
Vol 8 (24) ◽  
pp. 1672-1672
Author(s):  
Guangbin Li ◽  
Wei Jiang ◽  
Yunteng Kang ◽  
Xiaojun Yu ◽  
Chengpeng Zhang ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16509-e16509
Author(s):  
Rong Feng Liu ◽  
Jian Shi ◽  
Xiaoyang Duan

e16509 Background: TRIM59 is the one of TRIM family characterized by an N-terminal really interesting new gene (RING)-finger domain, followed by two zinc-finger domains named B2 box and a coiled-coil (CC). Ubiquitination plays a vital role in the degradation of many kinds of proteins that function in the intracellular signaling pathway, cell cycle, DNA repair and transcriptional regulation. Because of the RING-finger domain, TRIM59 protein functions as E3 ubiquitin ligase activity and can selectively target ubiquitin-modified proteins for proteasomes or degradation. In additional, accumulating finding results have shown the TRIM proteins promote positively or negatively carcinogenesis. Here we focus on the TRIM59 protein: oncogenic activity in the promoting proliferation and metastasis of esophageal cancer cell. Methods: None. Results: Human esophageal cancer cells’ motility adopts various modes resulting in the HESC progression and poor survival of patients. We proved that TRIM59 is aberrantly up-regulated in metastatic human esophageal cancer (hESC) than adjacent normal esophageal tissue, which is on behalf of poor survival and advanced TNM state among the hESC patients. At the molecular level, we proved TRIM59 as an E3 putative ubiquitin ligase targets the p53 protein leading to the increased degradation of p53 resulting in the less chemotherapy sensitivity to cisplatin. TRIM59 knockdown in hESC cell lines reduced TRIM59 expression and promotes p53 protein level and decreased the proliferation, clone formation, migration. At the same time, hESC cell lines showed more sensitive to the cisplatin in the cell line treated with knockdown of TRIM59. These findings establish the relationship between TRIM59 and p53 and chemotherapy sensitivity of cisplatin and TRIM59 may be a promising prognostic indicator for esophageal squamous cell carcinoma (ESCA) patients. Conclusions: We have confirmed that the up-regulation of TRIM59 in human esophageal cancer tissues closely correlates with poor prognosis of patients and TRIM59 serves as an oncogene promoting the proliferation and metastasis of esophageal cancer. The study demonstrates that knockdown of TRIM59 inhibited the growth and invasion of Eca109 cancer cells and strengthened the chemosensitivity to cisplatin through the mechanism of increasing the p53 expression. These results suggest that combination of TRIM59 knockdown with cisplatin might provide a promising strategy to treat the patients with esophageal cancer.


2015 ◽  
Vol 74 ◽  
pp. 89-94 ◽  
Author(s):  
Yangqing Pei ◽  
Pan Wang ◽  
Hongchun Liu ◽  
Fucheng He ◽  
Liang Ming

Gene ◽  
2018 ◽  
Vol 677 ◽  
pp. 308-316 ◽  
Author(s):  
Dan Zhang ◽  
Wei Yang ◽  
Shuwei Wang ◽  
Fei Wang ◽  
Dayong Liu ◽  
...  

2018 ◽  
Vol 53 (7) ◽  
pp. 769-776 ◽  
Author(s):  
Qiong Zhang ◽  
Huaiyong Gan ◽  
Wenqing Song ◽  
Damin Chai ◽  
Shiwu Wu

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Huiyan Tang ◽  
Chao Li ◽  
Yongsheng Wang ◽  
Liqiang Deng

Sufentanil is a μ-opioid receptor agonist, widely used in intraoperative and postoperative analgesia of esophageal cancer. This study investigated the effects of sufentanil on the proliferation, invasion, and metastasis of esophageal carcinoma cells and its molecular mechanisms. Human esophageal carcinoma cells CaES-17 and Eca-109 were cultured in vitro. Different concentrations of sufentanil (1 and 10 μmol/L) were added to the experimental group. MTT was used to detect the proliferative activity of esophageal carcinoma cells. The migration ability of esophageal carcinoma cells was measured by the scratch test. Transwell was used to detect the invasive ability of esophageal carcinoma cells. The EMT marker expression was detected by qPCR. Meanwhile, effects of sufentanil on NF-κB and Snail expression and nucleation were evaluated. Establish a subcutaneous xenograft tumor model of nude mice with esophageal carcinoma cells and evaluate the antitumor effect of sufentanil. Sufentanil can inhibit the proliferation, invasion, and migration of CaES-17 and Eca-109 cells and has a dose-dependent relationship. The molecular mechanism showed that sufentanil could upregulate the expression of E-cadherin and inhibit the expression of vimentin. Sufentanil can inhibit the expression of NF-κB and Snail, as well as the nuclear expression of NF-κB and Snail. Xenograft tumor model results showed that sufentanil could inhibit tumor proliferation and NF-κB and Snail expression in tumor tissues of nude mice. Sufentanil inhibits esophageal cancer epithelial-mesenchymal transition (EMT) by acting on NF-κB and Snail signaling pathways to inhibit proliferation and metastasis of esophageal cancer.


2016 ◽  
Vol 1 (13) ◽  
pp. 169-176
Author(s):  
Lisa M. Evangelista ◽  
James L. Coyle

Esophageal cancer is the sixth leading cause of death from cancer worldwide. Esophageal resection is the mainstay treatment for cancers of the esophagus. While curative, surgical resection may result in swallowing difficulties that require intervention from speech-language pathologists (SLPs). Minimally invasive surgical procedures for esophageal resection have aimed to reduce morbidity and mortality associated with more invasive techniques. Both intra-operative and post-operative complications, regardless of the surgical approach, can result in dysphagia. This article will review the epidemiological impact of esophageal cancers, operative complications resulting in dysphagia, and clinical assessment and management of dysphagia pertinent to esophageal resection.


Sign in / Sign up

Export Citation Format

Share Document